Cargando…

Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children

Several vaccines and extended half-life monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) have shown promise in clinical trials. We used age-structured transmission models to predict the possible impact of various RSV prevention strategies including maternal immunization, live-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Zhe, Weinberger, Daniel M., Pitzer, Virginia E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612629/ https://www.ncbi.nlm.nih.gov/pubmed/36302926 http://dx.doi.org/10.1038/s41541-022-00550-5

Ejemplares similares

Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis
por: Laufer, Rachel S., et al.
Publicado: (2023)

Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups
por: Zheng, Zhe, et al.
Publicado: (2022)

Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19
por: Abraham, Jonathan
Publicado: (2022)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Local variations in the timing of RSV epidemics
por: Noveroske, Douglas B., et al.
Publicado: (2016)

Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin
por: Roy, Chad J., et al.
Publicado: (2020)

Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines
por: Prunas, Ottavia, et al.
Publicado: (2023)

Chimeric antibodies with extended half-life in ferrets
por: Nesspor, Thomas C, et al.
Publicado: (2014)

The Impact of RSV Hospitalization on Children’s Quality of Life
por: Wrotek, August, et al.
Publicado: (2023)

Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein
por: Chen, Zhifeng, et al.
Publicado: (2016)

Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
por: Caidi, Hayat, et al.
Publicado: (2012)

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
por: Endt, Kathrin, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children
por: Weinberger, Daniel M, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
por: Yu, Xiang-Qing, et al.
Publicado: (2016)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children
por: Zheng, Zhe
Publicado: (2022)

Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
por: Shen, Yijun, et al.
Publicado: (2017)

Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
por: Ananworanich, Jintanat, et al.
Publicado: (2021)

Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies
por: Jacobs, Lotte, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Current Insights in the Development of Efficacious Vaccines Against RSV
por: Soto, Jorge A., et al.
Publicado: (2020)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
por: Mejías, Asunción, et al.
Publicado: (2007)

A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics
por: Jones, Hannah M., et al.
Publicado: (2020)

Incorporating efficacy data from initial trials into subsequent evaluations: Application to vaccines against respiratory syncytial virus
por: Warren, Joshua L., et al.
Publicado: (2023)

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products
por: Tortella, Bartholomew J., et al.
Publicado: (2018)

Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model
por: Zeitlin, Larry, et al.
Publicado: (2013)

New Anti-RSV Nucleoprotein Monoclonal Antibody Pairs Discovered Using Rabbit Phage Display Technology
por: Baurand, Pierre-Emmanuel, et al.
Publicado: (2023)

Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age
por: Jans, Jop, et al.
Publicado: (2017)

Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
por: Koivisto, Karoliina, et al.
Publicado: (2021)

Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal()
por: Chu, Helen Y., et al.
Publicado: (2017)

Community factors associated with local epidemic timing of respiratory syncytial virus: A spatiotemporal modeling study
por: Zheng, Zhe, et al.
Publicado: (2021)

M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against RSV Challenge
por: Welliver, Robert C, et al.
Publicado: (2017)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

Erratum: Airway T cells protect against RSV infection in the absence of antibody
por: Kinnear, E, et al.
Publicado: (2017)

2770. Intrapulmonary Vaccination with an M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against an RSV Challenge
por: Welliver, Robert C, et al.
Publicado: (2019)

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
por: Davé, Emma, et al.
Publicado: (2016)

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use
por: Sparrow, Erin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1smvbmnqvnbmg16pnt55es9lih